What You Should Know:
– Biobeat announced the launch of its new wearable and continuous ambulatory blood pressure monitoring (ABPM) device, currently the only cuffless ABPM solution in the world.
– As blood (BP) measurement has shown to be crucial in the early detection and prevention of clinical disorders, Biobeat’s cuffless ABPM device can act as a decisive indicator of patient health, tracking patient cardiac data continuously in real-life settings outside of the physician’s office to provide a more accurate view of patient health.
How It Works
Biobeat’s disposable wearable chest-monitor includes an easy and intuitive patient self-set-up, requiring no assistance from a clinician or technician. The device measures diastolic and systolic BP, as well as heart rate, mean arterial pressure, cardiac output, and systemic vascular resistance. Measurements are accessible via the patient’s mobile phone via a designated app, and are also readily available for physicians through an online report-analysis web-application. By utilizing the wide range of vital signs measured by the Biobeat device, the report enables health care providers to gain a profound understanding of the root cause of the issues identified and truly personalize medicine, allowing for more precise prescription and titration of medications and therapies.
Recent ABPM Peer-Reviewed Clinical Study Results
The new product launch is supported by a recently published peer-reviewed clinical study. The study, which compared Biobeat’s wearable wrist-monitoring device to a standard cuff-based ABPM device, found that Biobeat’s device has ABPM monitoring capabilities comparable to the standard cuff-based ABPM device. Findings also demonstrated standard cuff-based ABPM devices resulted in higher blood pressure values, likely due to a startle effect resulting from the inflating cuff, and that Biobeat’s wireless wrist monitor caused significantly less inconvenience compared to the cuff-based device. Additionally, the study demonstrated a 24-hour bias of -1.1 mmHg for both diastolic blood pressure (DBP) and systolic blood pressure (SBP), with a mean daytime bias of -1.9 mmHg for DBP and SBP, and an even smaller nighttime bias was determined.
“In addition to systolic and diastolic BP, Biobeat’s novel ABPM device measures cardiac output, stroke volume, heart rate, mean arterial pressure, and systemic vascular resistance, providing a comprehensive clinical understanding of an individual’s health status,” added Professor Arik Eisenkraft, MD, Chief Medical Officer of Biobeat. “This clinical study highlights the benefit of our device over commonly-used cuff-based ABPM devices, with a remarkable ease-of-use and lack of bias resulting from the mechanical effects of the inflating cuff.”
